N/A
Completed N=100
RexMedical- Option* Vena Cava Filter IDE Study
Source: ClinicalTrials.gov NCT00488865 ↗Enrolled (actual)
100
Serious AEs
65.0%
Results posted
Aug 2010
Primary outcomePrimary: Percentage of Participants With Clinical Success — 88 Percent of Participants
Summary
This study is designed to evaluate the safety and efficacy of the RexMedical Option* Vena Cava Filter in the treatment of patients who are at increased risk for Pulmonary Embolism and require caval interruption.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Clinical Success |
88 | — |
| PRIMARY Percentage of Participants With Retrieval Clinical Success |
92 | — |
| SECONDARY Placement Technical Success |
100 | — |
Eligibility Criteria
Key Inclusion Criteria
- Patient is at least 18 years of age
- Patient requires temporary or permanent caval interruption
Key Exclusion Criteria
- Patient has pre-existing filter implanted in her/her vasculature or has undergone filter retrieval within 60 days prior to study device implant
- Patient is currently enrolled in another investigational device or drug trial
Data sourced from ClinicalTrials.gov (NCT00488865). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.